Affinity Clinical Research
Latest News and InformationInvestigator-Initiated Research – Common Mistakes
Investigator-Initiated research is exciting research. It is attempting to answer questions asked by those at the coal face. Who better than clinicians to know what problems face our patient day-to-day? I have been involved with Investigator-Initiated research for...
read moreStaffing Clinical Trials
The biggest expense of a research project is people. Hiring qualified, experienced staff is not cheap. It is, however, necessary. Without the right people, it is unlikely the research project will make it out of the starting gates, let alone to the finishing line. ...
read moreApproval of New Lung Cancer Trial on World Lung Cancer Day
It is very fitting that on World Lung Cancer Day we can announce the approval of the MERU study, a new trial for patients with extensive stage Small Cell Lung Cancer. The MERU study will evaluate the efficacy of rovalpituzumab tesirine (Rova-T) as maintenance therapy...
read moreHead and Neck study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is now open to recruitment. Head and Neck cancer includes cancer of the tongue, gum, mouth, salivary glands, tonsils, pharynx, nasal...
read moreMelanoma study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for metastatic or advanced melanoma is now open to recruitment (and we have already recruited our first patient!). More information about the study can be found here. If you would to discuss this study, you can...
read moreInternational Clinical Trials Day 2017
Today we celebrate International Clinical Trials Day. We would like to take this opportunity to thank all our volunteers, patients, trial participants and their families. Without you, our wonderful researchers could not be doing the work that they do. Thank you also...
read moreInternational Clinical Trials Day – 20th May
On the 20th May 1747 James Lind began his trials into the cause of scurvy. Lind's trial is recognised as one of the first clinical experiments in the history of medicine. Every year on the 20th May we pause to commemorate the work of James Lind and the countless...
read more
Happy Birthday to Us!
Today is our official first birthday and I am very excited to celebrate this milestone. In the last twelve months, Affinity has achieved more than I could have hoped for. Our goal at the beginning of the year was to find and initiate one study with maybe a second in...
read more
GCP Thursdays: Informed Consent
When faced with treatment decisions, it is not uncommon for patients to ask "What do you think I should do?". This is only natural - when faced with making a difficult decision, it makes sense to ask for expert advice. And as a health professional who wants what's...
read more
GCP Thursdays: Serious v Severe AEs
There is often a lot of confusion about the difference between a severe adverse event and a serious adverse event. Severity is a grading. Adverse Events (AEs) can be classified as mild, moderate or severe. An AE can be severe without being a Serious Adverse Event....
read moreInvestigator-Initiated Research – Common Mistakes
Investigator-Initiated research is exciting research. It is attempting to answer questions asked by those at the coal face. Who better than clinicians to know what problems face our patient day-to-day? I have been involved with Investigator-Initiated research for...
read moreStaffing Clinical Trials
The biggest expense of a research project is people. Hiring qualified, experienced staff is not cheap. It is, however, necessary. Without the right people, it is unlikely the research project will make it out of the starting gates, let alone to the finishing line. ...
read moreApproval of New Lung Cancer Trial on World Lung Cancer Day
It is very fitting that on World Lung Cancer Day we can announce the approval of the MERU study, a new trial for patients with extensive stage Small Cell Lung Cancer. The MERU study will evaluate the efficacy of rovalpituzumab tesirine (Rova-T) as maintenance therapy...
read moreHead and Neck study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is now open to recruitment. Head and Neck cancer includes cancer of the tongue, gum, mouth, salivary glands, tonsils, pharynx, nasal...
read moreMelanoma study Now Open
We are excited to announce the Dynavax DV3-MEL-01 study for metastatic or advanced melanoma is now open to recruitment (and we have already recruited our first patient!). More information about the study can be found here. If you would to discuss this study, you can...
read moreInternational Clinical Trials Day 2017
Today we celebrate International Clinical Trials Day. We would like to take this opportunity to thank all our volunteers, patients, trial participants and their families. Without you, our wonderful researchers could not be doing the work that they do. Thank you also...
read moreInternational Clinical Trials Day – 20th May
On the 20th May 1747 James Lind began his trials into the cause of scurvy. Lind's trial is recognised as one of the first clinical experiments in the history of medicine. Every year on the 20th May we pause to commemorate the work of James Lind and the countless...
read more
Happy Birthday to Us!
Today is our official first birthday and I am very excited to celebrate this milestone. In the last twelve months, Affinity has achieved more than I could have hoped for. Our goal at the beginning of the year was to find and initiate one study with maybe a second in...
read more
GCP Thursdays: Informed Consent
When faced with treatment decisions, it is not uncommon for patients to ask "What do you think I should do?". This is only natural - when faced with making a difficult decision, it makes sense to ask for expert advice. And as a health professional who wants what's...
read more
GCP Thursdays: Serious v Severe AEs
There is often a lot of confusion about the difference between a severe adverse event and a serious adverse event. Severity is a grading. Adverse Events (AEs) can be classified as mild, moderate or severe. An AE can be severe without being a Serious Adverse Event....
read more